Abeona Therapeutics Inc ABEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.55
- Day Range
- $7.44–7.69
- 52-Week Range
- $2.77–9.01
- Bid/Ask
- $7.57 / $7.85
- Market Cap
- $208.99 Mil
- Volume/Avg
- 113,688 / 342,889
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 44.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 84
Comparables
Valuation
|
Metric
|
ABEO
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 13.17 | 12.65 | 3.69 |
Price/Sales | 44.96 | 111.01 | 2,296.18 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABEO
CBAY
VRDN
Financial Strength
|
Metric
|
ABEO
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 4.07 | 10.70 | 17.93 |
Current Ratio | 4.15 | 10.96 | 18.26 |
Interest Coverage | −133.70 | −5.27 | −137.76 |
Quick Ratio
ABEO
CBAY
VRDN
Profitability
|
Metric
|
ABEO
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −64.39% | −30.06% | −42.76% |
Return on Equity (Normalized) | −211.48% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −163.63% | −30.87% | −50.70% |
Return on Assets
ABEO
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dyqlrkvhcp | Lrnt | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zcxmjmtyg | Nmvrg | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xnwmbrtl | Ycclq | $98.6 Bil | |
MRNA
| Moderna Inc | Szdmfnxzc | Zvtv | $41.0 Bil | |
ARGX
| argenx SE ADR | Szhvmlg | Wgcx | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Thqdgwnct | Jkcg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dlncrnx | Jbzplr | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wjbkhjx | Rcwqwy | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mnkcvnzqqv | Ccbnls | $12.6 Bil | |
INCY
| Incyte Corp | Kmtkdqrxw | Hsqlwyk | $12.0 Bil |